[go: up one dir, main page]

WO2013188016A3 - Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant - Google Patents

Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant Download PDF

Info

Publication number
WO2013188016A3
WO2013188016A3 PCT/US2013/039592 US2013039592W WO2013188016A3 WO 2013188016 A3 WO2013188016 A3 WO 2013188016A3 US 2013039592 W US2013039592 W US 2013039592W WO 2013188016 A3 WO2013188016 A3 WO 2013188016A3
Authority
WO
WIPO (PCT)
Prior art keywords
ionizing radiation
exposure
surfactant
pulmonary
surfactant therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/039592
Other languages
English (en)
Other versions
WO2013188016A2 (fr
Inventor
Robert Segal
Melpo Christofidou-Solomidou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Windtree Therapeutics Inc
Original Assignee
Discovery Laboratories Inc
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Laboratories Inc, University of Pennsylvania Penn filed Critical Discovery Laboratories Inc
Publication of WO2013188016A2 publication Critical patent/WO2013188016A2/fr
Publication of WO2013188016A3 publication Critical patent/WO2013188016A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0082—Lung surfactant, artificial mucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des thérapies pour le traitement ou la prévention d'états résultant d'une exposition directe ou indirecte du tissu pulmonaire à un rayonnement ionisant. En particulier, des régimes de traitement ou de prévention d'états résultant d'une exposition directe ou indirecte du tissu pulmonaire à un rayonnement ionisant impliquent l'administration de surfactants pulmonaires. Dans certains modes de réalisation, le surfactant pulmonaire est un surfactant KL4.
PCT/US2013/039592 2012-05-04 2013-05-04 Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant Ceased WO2013188016A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261642856P 2012-05-04 2012-05-04
US61/642,856 2012-05-04
US201361794036P 2013-03-15 2013-03-15
US61/794,036 2013-03-15

Publications (2)

Publication Number Publication Date
WO2013188016A2 WO2013188016A2 (fr) 2013-12-19
WO2013188016A3 true WO2013188016A3 (fr) 2014-04-10

Family

ID=48875145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039592 Ceased WO2013188016A2 (fr) 2012-05-04 2013-05-04 Thérapie utilisant des surfactants pour exposition à un rayonnement ionisant

Country Status (1)

Country Link
WO (1) WO2013188016A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190067150A (ko) 2016-06-07 2019-06-14 더 트러스티즈 오브 더 유니버시티 오브 펜실베니아 이식과 관련된 허혈/재관류 손상으로부터 장기를 보호하기 위한 조성물 및 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
WO2006055532A2 (fr) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Procedes de production de formulations de tensioactifs pulmonaires par lyophilisation et formulations et utilisations correspondantes
WO2007005672A2 (fr) * 2005-06-30 2007-01-11 The Scripps Research Institute Traitement et prevention de maladies et de situations respiratoires
US20100317565A1 (en) * 2007-06-04 2010-12-16 Rentschler Beteiligungs Gmbh Novel Peptides and Their Use for the Treatment of Edema
EP1558273B1 (fr) * 2002-04-25 2011-08-17 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574325A (en) 1896-12-29 Joseph s
US502495A (en) 1893-08-01 klijsel
US5840527A (en) 1984-12-11 1998-11-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Recombinant alveolar surfactant protein
US4659805A (en) 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4918161A (en) 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
JP2602968B2 (ja) 1987-11-04 1997-04-23 カリフォルニア バイオテクノロジー インコーポレイテッド 肺胞の界面活性タンパク類
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4861756A (en) 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5238920A (en) 1989-08-22 1993-08-24 Abbott Laboratories Pulmonary surfactant protein fragments
EP0458167B1 (fr) 1990-05-21 1997-04-23 Abbott Laboratories Conjugés acide gras-tensioactif pulmonaire
US5272252A (en) 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
ES2192190T3 (es) 1992-04-10 2003-10-01 Abbott Lab Fragmentos proteicos tensioactivos pulmonares.
US5302481A (en) 1993-06-07 1994-04-12 Xerox Corporation Toner compositions with negative charge enhancing complexes
FI962355L (fi) 1993-12-08 1996-06-06 Tokyo Tanabe Co Uusia synteettisiä peptidejä, niitä sisältävä keuhkojen pinta-aktiivinen aine ja lääke hengityselinsairausoireyhtymän hoitamiseen
DE4418936A1 (de) 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6120795A (en) 1996-03-27 2000-09-19 Ortho Pharmaceutical Corp. Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6660833B1 (en) 2000-02-29 2003-12-09 Harbor-Ucla Research And Education Institute Respiratory distress syndrome therapy with peptide analogs of human SP-B
EP1539284B1 (fr) 2002-09-06 2020-01-29 Philip Morris Products S.a.s. Generateur aerosols et procede de generation d'aerosols
US8580321B2 (en) 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
BRPI0908556B8 (pt) 2008-03-17 2021-06-22 Discovery Lab Inc adaptador para distribuir um agente ativo aerosolizado e sistema para fornecer um agente ativo aerosolizado
RU2011115187A (ru) 2008-09-19 2012-10-27 Максиджен, Инк. (Us) Способ лечения индуцированной радиацией нейтропении путем введения множественно конъюгированного с полиэтиленгликолем варианта гранулоцитарного колониестимулирущего фактора (г-ксф)

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558273B1 (fr) * 2002-04-25 2011-08-17 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
US20060078506A1 (en) * 2004-05-20 2006-04-13 Ralph Niven Methods, systems and devices for noninvasive pulmonary delivery
WO2006055532A2 (fr) * 2004-11-15 2006-05-26 Discovery Laboratories, Inc. Procedes de production de formulations de tensioactifs pulmonaires par lyophilisation et formulations et utilisations correspondantes
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
EP1833503B1 (fr) * 2004-12-23 2013-07-31 Discovery Laboratories, Inc. Formulations de tensioactif pulmonaire
WO2007005672A2 (fr) * 2005-06-30 2007-01-11 The Scripps Research Institute Traitement et prevention de maladies et de situations respiratoires
US20100317565A1 (en) * 2007-06-04 2010-12-16 Rentschler Beteiligungs Gmbh Novel Peptides and Their Use for the Treatment of Edema

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Discovery Laboratories 10-K 2013", 15 March 2013 (2013-03-15), pages 1 - 133, XP055101943, Retrieved from the Internet <URL:http://www.wikinvest.com/stock/Discovery_Laboratories_(DSCO)/Filing/10-K/2013/F107474757> [retrieved on 20140213] *
ANONYMOUS: "Discovery Labs Initiates Research Projects with Leading Research Institutions and US Government Agencies to Assess KL4 Surfactant Utility in Acute Lung Injury", 27 September 2012 (2012-09-27), pages 1 - 3, XP055093034, Retrieved from the Internet <URL:http://www.discoverylabs.com/2012pr/092712-PR.pdf> [retrieved on 20131212] *
ANONYMOUS: "form10q.htm", 14 November 2012 (2012-11-14), pages 1 - 48, XP055093046, Retrieved from the Internet <URL:http://www.sec.gov/Archives/edgar/data/946486/000114036112047325/form10q.htm> [retrieved on 20131212] *
ANONYMOUS: "KL4 Surfactant to Mitigate Radiation-Induced Lung Injury | SBIR.gov", 2012, pages 1 - 2, XP055093121, Retrieved from the Internet <URL:http://www.sbir.gov/sbirsearch/detail/399806> [retrieved on 20131212] *
ANONYMOUS: "Project Information - 1R43AI102308-01 - Details", 19 June 2012 (2012-06-19), pages 1, XP055093058, Retrieved from the Internet <URL:http://projectreporter.nih.gov/project_info_details.cfm?aid=8393586&icde=0> [retrieved on 20131212] *
ANONYMOUS: "Project Information - 1R43AI102308-01", 19 June 2012 (2012-06-19), pages 1 - 2, XP055093053, Retrieved from the Internet <URL:http://projectreporter.nih.gov/project_info_description.cfm?aid=8393586&icde=0> [retrieved on 20131212] *
KRISHNAN RAGHAVENDRAN ET AL: "Surfactant Therapy for Acute Lung Injury and Acute Respiratory Distress Syndrome", CRITICAL CARE CLINICS, vol. 27, no. 3, 1 July 2011 (2011-07-01), pages 525 - 559, XP055093032, ISSN: 0749-0704, DOI: 10.1016/j.ccc.2011.04.005 *

Also Published As

Publication number Publication date
WO2013188016A2 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
HK1216175A1 (zh) 治療性化合物和組合物
IN2015DN01156A (fr)
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
ZA201606320B (en) Human plasma kallikrein inhibitors
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
WO2014062720A3 (fr) Méthodes de traitement du cancer
IN2014DN09173A (fr)
MY169328A (en) Compositions for the treatment of dry eye
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
EP3065768A4 (fr) Thérapie pour le traitement ou la prévention d&#39;états associés au saignement ou à l&#39;hypocoagulation
MX2015010829A (es) Compuestos terapeuticos y sus usos.
EP3212658A4 (fr) Analogues de 2&#39;,2&#39;-dihalo-nucléosides utilisables en vue du traitement d&#39;infections par des virus de la famille des flaviviridae et du cancer
HK1217092A1 (zh) 治疗性化合物及其用途
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
EP3206685A4 (fr) Prévention ou traitement de troubles du sommeil au moyen d&#39;une formulation de dexmédétomidine
EP2869819A4 (fr) Compositions, procédés et/ou dispositifs destinés à la prévention et/ou au traitement d&#39;affections de type sécheresse oculaire
EP3134423A4 (fr) Analogues de nucléosides disubstitués en 2&#39; pour le traitement des virus de la famille des flaviviridae et du cancer
EA201491500A1 (ru) Способы лечения фиброза
HK1199640A1 (en) Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2013185048A3 (fr) Inhibiteurs d&#39; atpase de type f1f0, à base de guanidine hétérocyclique et leurs utilisations thérapeutiques
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EP2991733A4 (fr) Cannabidiol destiné à la prévention et au traitement de la maladie du greffon contre l&#39;hôte

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13741890

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13741890

Country of ref document: EP

Kind code of ref document: A2